This table lists all the major pharma collaborations, acquisitions and mergers agreed during December 2014.
For an indepth analysis of these deals, read ‘Pharma deals during December 2014’
|
Licensor acquired / licensee acquirer |
Product / technology |
Deal type |
Headline ($m) |
| Cubist / Merck & Co | Portfolio of marketed and late stage antibiotics | Company acquisition | 9,500 |
| Avanir Pharmaceuticals / Otsuka Pharmaceutical | Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect | Company acquisition | 3,500 |
| *Astellas/ J&J | ASP015K, an oral JAK inhibitor for RA (p3) | Exercise of opt-out/ termination | **945 |
| Macrogenics / J&J | MGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical) | Licence | 700 |
| Cytokinetics / Astellas Pharma | CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1) | Expansion of collaboration/ amended agreement | 675 |
| Halozyme Therapeutics / J&J | ENHANZE rHuPH20 delivery technology for up to 5 targets | Collaboration, licence | 581 |
| Opko Health / Pfizer | Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3) | Licence | 570 |
| Adocia / Eli Lilly | BioChaperone Lispro (ultra-rapid insulin) based on BioChaperone technology (p1b) | Licence, collaboration | 570 |
| Dutalys / Roche | DutaMab technology for development of fully human, bispecific antibodies | Company acquisition | 489 |
| PneumRx / BTG | Portfolio of medical devices for interventional pulmonology inc RePneu Coil | Company acquisition | 475 |
| ***GeNeuro / Servier | GNbAC1, mab to inhibit progression of MS without suppressing the immune system (p2) | Collaboration, option to license + take equity stake | 455 |
| Zosano Pharma / Eli Lilly | ZP-PTH (parathyroid hormone 1-34) delivered via microneedle patch system (p2) | Licence | 440 |
| OncoEthix / Merck & Co | Lead product oral BET inhibitor, OTX015 for oncology indications (p1b) | Company acquisition | 375 |
| Evotec / Sanofi | R&D alliance to progress Sanofi discovery phase compounds to preclinical stage (inc Sanofi discovery facility with 200 scientists) | Exclusive negotiations to create 5-year strategic alliance | 310 |
| Array BioPharma / Oncothyreon | ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1) | Licence – amended agreement | †300 |
| Spark Therapeutics / Pfizer | Multiple haemophilia B gene therapy products (preclinical) | Gene therapy collaboration | 280 |
| Xencor / Novo Nordisk | XmAb technologies, inc bispecific and immune inhibitor technologies, for undisclosed target | Collaboration, licence | 175 |
| Phylogica / Genentech | Phylomer drug discovery platform for novel antibiotics | Research & licensing agreement | 142.5 |
| Boston Heart Diagnostics / Eurofins Scientific | Diagnostics tests for chronic conditions including cardiovascular diseases and diabetes | Company acquisition | 140 |
| Sevion Therapeutics / J&J | Spatially addressed antibody discovery platform | Research collaboration, options to license | 125 |
| ††Ariad Pharmaceuticals / Otsuka Pharmaceutical | Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph+ALL (JP NDA) | Co-development and commercialisation agreement | 77.5 |
All deals global unless otherwise stated:
* ex Japan
** original deal headline value
***ex US, JP
† If Oncothyreon is acquired with 3 years of effective date, Array eligible for up to $280m milestones
†† JP + 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph+ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia)
